Takeda Pharmaceutical Company (4502) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Launches and psoriasis opportunity
MIMRYLO and ORZEYFUL launches are performing well; resources are allocated to both, while zasocitinib has FDA priority review with a decision expected in March.
Zasocitinib delivered 2.5x the effect of deucravacitinib on PASI 100 in a head-to-head trial; week-16 PASI 100 was ~36% by point estimate.
U.S. oral psoriasis treatments represent ~10% of the market; zasocitinib has no food restriction, fast onset, durability and activity across patient types.
Management sees room for another effective oral option as many patients prefer trying an oral before injectable therapy.
Pipeline and growth strategy
Strategy is to build depth in existing franchises, including IBD assets alongside ENTYVIO; the three launches begin a new cohort of growth assets.
Horizon One is expected to deliver low growth as marketed products mature; savings will be reinvested in launches and pipeline, with core operating profit margins protected.
Horizon Two begins as the first launches scale and a second product wave launches, supporting longer-term sustainable growth.
ORZEYFUL targets narcolepsy type 1; TAK-360 and TAK-495 are clinical orexin-2 agonists, with another molecule planned for the clinic and next-generation orexin-1 research underway.
Zasocitinib psoriatic arthritis data are expected next year; UC and Crohn's phase II data are expected by fiscal year-end, with phase III preparations underway pending Crohn's results and dose decisions.
Investment and capital allocation
Commercial investment is nearly JPY 100bn this year and may rise next year, the first full year for the three launches; transformation savings fund launch spending.
Savings are expected to be fully annualized next year, alongside annualized launch spending and increased phase III investment; management cautioned that launches are not typically profit-accretive in year one.
Free cash flow supports growth investment, deleveraging and dividends; the progressive dividend policy targets maintaining or increasing dividends, with ~40% of FCF going to dividends.
Net debt/adjusted EBITDA is 2.5x; the target is 2x before U.S. ENTYVIO biosimilar entry.
Business development will focus on complementary assets that deepen existing therapeutic areas, especially earlier-stage pipeline; attractive late-stage opportunities remain under review.
Latest events from Takeda Pharmaceutical Company
- FX and savings lifted FY2026 guidance despite H1 CER sales softness.4502
Q2 2027 - Strategic shift and robust pipeline drive upcoming launches and data milestones.4502
Morgan Stanley 24th Annual Global Healthcare Conference - Q1 revenue up 10.2% on FX; core profit flat at CER; new launches offset mature declines.4502
Q1 2027 - Three major launches and a transformation plan set the stage for renewed growth and efficiency.4502
Jefferies Global Healthcare Conference 2026 - Zasocitinib achieved rapid, durable skin clearance and strong safety in phase III psoriasis trials.4502
Study Update - Oveporexton phase III trials in NT1 achieved robust efficacy and safety across all symptom domains.4502
Study Update - Net profit rose 30.4% despite revenue decline, with pipeline and cash flow strength supporting guidance.4502
Q1 2026 - H1 revenue and profit surged, guidance raised, but H2 faces Vyvanse erosion and higher R&D costs.4502
Q2 2025 - Q1 revenue up 2.1% at CER, but net profit faces pressure from costs and Vyvanse erosion.4502
Q1 2025 - Growth and launch products drove revenue and margin gains, with flat core outlook and higher dividend.4502
Q4 2025